VP, Market Access
Mark Hopman serves as Vice President, Market Access at Pear Therapeutics, responsible for creating and expanding third party coverage for PDTs across all US payer segments. He brings to Pear over 21 years of Health Care experience.
Prior to joining Pear, Mark spent seven years at Dexcom as a leader on the Market Access team where he helped transform continuous glucose monitoring (CGM) from an emerging technology to the standard of care for patients with insulin-dependent diabetes. During his tenure at Dexcom, CGM access vastly expanded across both commercial and government segments, making the technology accessible to most indicated patients in the US.
Mark earned an MBA from Xavier University and a Bachelor of Science, Pharmacy from The Ohio State University. He is also a registered pharmacist in Ohio.